Status:
COMPLETED
BaSES Trial: Basel Starch Evaluation in Sepsis
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Fresenius AG
Conditions:
Sepsis
Severe Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Background: In patients with severe sepsis and septic shock early aggressive volume replacement reduced mortality. Standard infusion therapy consists of crystalloid infusions. The role of modern, low ...
Eligibility Criteria
Inclusion
- Patients with suspected or proven infection and 2 of the following 6 criteria:
- Body temperature \<36 or \>38.3° celsius
- Heart rate \> 90 beats/min
- Tachypnea \> 20/min or a arterial pCO2 below 4.25 kPa
- White blood cell count higher than 12.000 or below 4.000 or more than 10% immature forms
- Systolic blood pressure \<90 mmHg or mean arterial pressure \< 65 mmHg
- Altered mental state or oliguria
Exclusion
- Pregnancy
- Age below 18
- Allergy against Hydroxyethyl starch
- Chronic renal insufficiency
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
231 Patients enrolled
Trial Details
Trial ID
NCT00273728
Start Date
May 1 2005
End Date
May 1 2011
Last Update
August 12 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Surgical ICU, University Hospital Basel
Basel, Switzerland, 4031
2
Medical ICU, Univesity Hospital Basel
Basel, Switzerland, CH-4031